Stocks outlook 2016
Jefferies, Sean Darby - 5,000 (): “Growth – Real and Nominal – is not likely to be a problem in 2022 as the US consumer, corporate, government and possibly the banks unleash their spending. China, rising capex but slowing consumption, the end of the ‘equity shrinkage’ bull case.”² But, it would still be adding liquidity, though at a slower pace, to the economy’s punch bowl-which already has plenty of liquidity from previous rounds of the Fed’s largess.“ (via LinkedIn)īank of America, Savita Subramanian - 4,600 (): “Drivers for our outlook: a higher discount rate, US GDP primacy vs. Yardeni Research, Ed Yardeni - 5,200 (): “Assuming, as I do, that Omicron, the new variant of Covid, will turn out to be no worse than the Delta variant, I still expect that the S&P 500 will continue to rise to new record highs… The Fed may decide to taper faster in response to higher-than-expected inflation. further delay in China reopening, supply-chain issues, labor shortages continue).” (via MarketWatch) delta, omicron), this needs to be seen in the context of higher natural and vaccine-acquired immunity, significantly lower mortality, and new antiviral treatments… With this in mind, the key risk to our outlook is a hawkish shift in policy, especially if post-pandemic dislocations persist (e.g. JPMorgan, Dubravko Lakos-Bujas - 5,050 (): “While there have been sporadic setbacks with COVID-19 variants (e.g. Higher volatility with potentially significant intra-year sector rotations depending on level of real yields.” The S&P closed on Friday at 4,538, which implies returns between -3% and +17%:īarclays - 4,800 (): “Household and corporate cash hoards should support modest earnings growth but persistent supply chain woes, reversal of goods consumption to trend and China hard-landing are key tail risks.“ (via Jonathan Ferro)ĭWS, David Bianco - 5,000 (): “2022 returns driven by earnings growth. Uerkwitz rates the stock at outperform but reduced his target price to $7 from $8.Below is a roundup of 14 of these 2022 forecasts for the S&P 500¹ including highlights from the strategists’ commentary. “We see these as validating our thesis as Fitbit being a key player in the digitization of health/wellness.” “Hardware issues aside, Fitbit Health Solutions continue to grow nicely, and management indicated relationships with leading healthcare providers continue to improve,” he wrote. Oppenheimer analyst Andrew Uerkwitz also stayed upbeat on the stock, arguing that the Versa Lite missteps are overshadowing progress in Fitbit Health Solutions, which saw revenue rise 41% in the first half of the year. He rates the stock a buy but lowered his price target to $5.75 from $7. Among Forte’s positives is that the company has a strong cash balance that accounts for more than half of its market value. Davidson analyst Tom Forte said he is “disappointed” by Fitbit’s weak outlook but still optimistic about the company overall. Opinion: Fitbit Versa Lite is a pretty good value if exercise is the goalĭ.A.
Meanwhile, devices sales are stagnating as both the novelty wears off and competition increases.” “However, it is taking longer than expected to roll out and expand these services. “Long-term, shares of Ftibit could expand if services revenue ultimately launches the company back to profitability,” he wrote.
#Stocks outlook 2016 drivers
Wedbush analyst Michael Pachter maintained his neutral rating on the stock, writing that he sees limited growth drivers for the company while profitability remains an “elusive” target. Apple Inc.’s Apple Watch offers that capability. Suva also argued that Fitbit’s opportunities are hampered by the fact that the company lacks “full two-way texting functionality” on its smartwatches. “While the company is going after the healthcare industry which is in need of great assistance from such products we are concerned Fitbit may not have the capital, personnel and time, to materially see traction in this sector,” he wrote in a note to clients. 3, 2016, when it fell 34%.Ĭiti Research analyst Jim Suva wrote that he has “big concerns” about Fitbit’s future, while maintaining a sell rating on the stock and cutting his price target to $2 from $5. Is down 20% in morning trading and on track to post its worst single-day drop since Nov.